🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting in excess of 82 million new cases per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the reality of rising global incidence, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Authorization

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to major issues, including infertility. Experts hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization marks a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

Based on findings released by a major medical journal, the new drug cured the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines two antibiotics. The research involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have shared hope. Access to a single-dose, oral treatment like this is described as a "game-changer" for gonorrhoea control. This is deemed crucial to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea around the world.